Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLARA ACTIVE PHARMA SCIENCES LIMITED Capital/Financing Update 2024

Jun 19, 2024

61842_rns_2024-06-19_92bcfbe4-1809-4753-ae13-9fccff408e65.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Communication Address: Solara Active Pharma Sciences Limited 2nd Floor, Admin Block 27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (Post) Chennai – 600 127, India Tel : +91 44 43446700 Fax : +91 44 47406190 E-mail : [email protected] www.solara.co.in

June 19, 2024

The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 541540 Scrip Code: SOLARA

Dear Sir/Madam,

Subject: Allotment of 1,19,98,755 partly paid-up equity shares of Solara Active Pharma Sciences Limited (“Company”) of face value of ₹ 10 each (“Equity Shares”) – Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

This is with reference to our intimation on the outcome of the meeting of the board of directors of the Company (“Board”) dated July 5, 2023, wherein the Board approved the raising of funds through rights issue and our intimation on the outcome of the meeting of the Rights Issue Committee dated May 9, 2024, approving the various terms of the Rights Issue and the Letter of Offer (“Letter of Offer”).

In relation to the aforesaid Rights Issue and the Letter of Offer and pursuant to the finalisation of the basis of allotment of the Rights Issue, in consultation with the BSE Limited, designated stock exchange; Choice Capital Advisors Private Limited, Lead Managers; Cameo Corporate Services Limited, Registrar to the Rights Issue; the Rights Issue Committee of the Board of Directors of the Company, at its meeting held today, i.e. June 19, 2024, inter alia, considered and approved the allotment of 1,19,98,755 partly paid up Equity Shares at a price of ₹ 375 per Rights Equity Share (including a premium of ₹ 365 per Rights Equity Share) wherein the applicants were required to pay ₹131.25 per Equity Share on application (face value of ₹ 3.50 per Rights Equity Share and premium of ₹ 127.75 per Rights Equity Share).

Consequent to the said Allotment, the paid-up equity share capital of the Company has increased from ₹ 36,00,52,670 divided into 3,60,05,267 fully paid up Equity Shares of face value of ₹10 each to ₹40,20,48,313 divided into 3,60,05,267 fully paid up Equity Shares of face value of ₹10 each and 1,19,98,755 partly paid up Equity Shares having face value of ₹ 10 each (where the Applicants were required to pay face value of ₹ 3.50 per Rights Equity Share on Application and the balance face value of ₹ 6.50 on subsequent call(s)).

The meeting commenced at 10.00 a.m. and concluded at 11.10 a.m.

You are requested to kindly take the above information on record.

Thanking you, Yours faithfully, For Solara Active Pharma Sciences Limited

SUDDAPALLI Digitally signed by SUDDAPALLI MURALIKRISHNA MURALIKRISHNA Date: 2024.06.19 11:27:28 +05'30' S. Murali Krishna Company Secretary

Solara Active Pharma Sciences Limited - CIN : L24230MH2017PLC291636 REGD. OFF: 201, Devavrata, Sector 17, Vashi Navi Mumbai - 400703. India/ Tel: 91-22-2789 2924 / 2789 3199 / Fax: 91-22-2789 2942